Literatur
- 1
Allgaier H -P, Deibert P, Olschewski M. et al .
Survival benefit of patients with inoperable hepatocellular carcinoma treated
by a combination of transarterial chemoembolization and percutaneous ethanol
injection - a single-center analysis including 132 patients.
Int J Cancer.
1998;
79
601-605
- 2
Befeler A S, di Bisceglie A M.
Hepatocellular carcinoma: diagnosis and treatment.
Gastroenterology.
2002;
122
1609-1619
- 3
Bruix J, Llovett J M.
HCC surveillance: who is the target population?.
Hepatology.
2003;
37
507-509
- 4 Chan C J, Chow P K, Tai B C. et al .Neoadjuvant and adjuvant therapy for operable
hepatocellular carcinoma. The Cochrane Library, Oxford 2002: 4
- 5
Kawata S, Yamasaki E, Nagase T. et al .
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma.
A randomized controlled trial.
Br J Cancer.
2001;
84
886-891
- 6
Lau W Y, Leung T W, Ho S K. et al .
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular
carcinoma: a prospective randomised trial.
Lancet.
1999;
353
797-801
- 7
Llovett J M, Bru C, Bruix J.
Prognosis of hepatocellular carcinoma: The BCLC Staging clssification.
Semin Liv Dis.
1999;
19
329-338
- 8
Llovet J M, Real M I, Montana X. et al .
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients
with unresectable hepatocellular carcinoma: a randomised controlled trial.
Lancet.
2002;
359
1734-1739
- 9
Marrero J A, Su G L, Wie W. et al .
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from
nonmalignant chronic liver disease in american patients.
Hepatology.
2003;
37
1114-1121
- 10
Mazzaferro V, Regalia E, Doci R. et al .
Liver transplantation for the treament for small hepatocellular carcinomas in
patients with cirrhosis.
N Engl J Med.
1996;
334
693-699
- 11
Nagashima I, Hamada C, Naruse K. et al .
Surgical resection for small hepatocellular carcinoma.
Surgery.
1996;
119
40-45
- 12
Nakamoto Y, Guidotti L G, Kuhlen C F. et al .
Immune pathogenesis of hepatocellular carcinoma.
J Exp Med.
1998;
188
341-350
- 13
Santagostino E, Colombo M, Rivi M. et al .
Six-month versus 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs
infected with the hepatitis C virus.
Blood.
2003;
102
78-82
- 14
Thorgeirsson S S.
Hunting for tumor suppressor genes in liver cancer.
Hepatology.
2003;
37
739-741
- 15
Velazquez R F, Rodriguez M, Navascues C A. et al .
Prospective analysis of risk factors for hepatocellular carcinoma in patients
with liver cirrhosis.
Hepatology.
2003;
37
520-527
- 16
von Weizsäcker F, Allgaier H P, Blum H E.
Prävention des hepatozellulären Karzinoms.
Schweiz Rundsch Med Prax.
2002;
91
1393-1395
Prof. Dr. med. Drs. h. c. H. E. Blum
Abteilung Innere Medizin II, Medizinische Universitätsklinik, Albert-Ludwigs-Universität
Freiburg
Hugstetter Straße 55
79106 Freiburg
Email: heblum@ukl.uni-freiburg.de
